This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OncoMed Pharmaceuticals Granted Patent For Methods Of Treating Cancer With Its Novel Wnt Pathway Targeting Antibody Vantictumab (OMP-18R5)

REDWOOD CITY, Calif., Aug. 22, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,507,442 to OncoMed for methods of treating cancer with its antibody vantictumab (OMP-18R5). Vantictumab targets and inhibits the Wnt pathway, which is believed to be an important CSC pathway. The patent expires in 2029.

Vantictumab was originally identified at OncoMed from the HuCAL GOLD ® antibody library (MorphoSys AG) by binding to the Frizzled-7 receptor and was later determined by OncoMed to bind a novel epitope conserved across five different Frizzled receptors. Vantictumab has demonstrated broad anti-CSC and anti-tumor activity in patient-derived xenograft models and is currently being evaluated in a Phase 1 clinical trial where it has provided early signs of single-agent activity in patients with neuroendocrine tumors. The antibody is part of OncoMed's collaboration with Bayer Pharma AG.

OncoMed previously received a U.S. patent claiming the composition of matter for vantictumab and has corresponding patents or pending patent applications covering vantictumab in fourteen additional countries and Europe. In addition, OncoMed has a robust patent portfolio of over 300 patents or pending patent applications, which includes multiple additional patent families related to vantictumab or its use. 

"OncoMed's new patent, together with its composition-of-matter patent, provides key patent coverage for vantictumab," said Paul Hastings, Chief Executive Officer of OncoMed.  "The issuance of this patent also further validates the novelty of this promising antibody and the innovative nature of OncoMed's ongoing discovery programs, which have not only produced vantictumab, but also four other anti-CSC agents currently in clinical trials."

About Vantictumab (OMP-18R5)

Vantictumab is a first-in-class antibody that has shown broad anti-CSC and anti-tumor activity in patient-derived xenograft tumor models.  Vantictumab inhibits a key signaling pathway in cancer, the Wnt pathway.  Specifically, vantictumab selectively targets Frizzled receptors, which are activators of Wnt signaling. Although vantictumab was originally identified by binding to Frizzled 7, the antibody selectively targets five different Frizzled receptors.  Vantictumab is currently being evaluated in a Phase 1 clinical trial.  Vantictumab is part of OncoMed's collaboration with Bayer Pharma AG.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs